Drug Trial Radar · NCT06719128
A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants
Last checked: Nov 19, 2026Latest source record: Sep 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Dec 6, 2024
Primary completion
Aug 25, 2025
Study completion Aug 25, 2025
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Dec 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to assess how olomorasib gets into the blood stream and how long it takes the body to remove it when administered to participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of olomorasib will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.
Conditions
- Hepatic Insufficiency
- Healthy
Interventions
OlomorasibDrug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics (PK): Maximum observed concentration (Cmax) of OlomorasibTime frame: Predose on Day 1 up to 96 hours postdose
- PK: Area under the concentration versus time curve from time zero to infinity (AUC0-inf) of OlomorasibTime frame: Predose on Day 1 up to 96 hours postdose
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Orange County Research Center
Lake Forest, California
Clinical Pharmacology of Miami
Miami, Florida
Orlando Clinical Research Center
Orlando, Florida
American Research Corporation at Texas Liver Institute
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.